سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver

Publish Year: 1396
Type: Journal paper
Language: English
View: 264

This Paper With 7 Page And PDF Format Ready To Download

Export:

Link to this Paper:

Document National Code:

JR_RYA-13-6_001

Index date: 24 August 2022

miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver abstract

BACKGROUND: microRNAs play pivotal roles in metabolism and other aspects of cell biology. microRNA-33 and liver X receptor (LXR) affect lipid metabolism and cholesterol trafficking. In this study, we evaluated effects of co-administration of miR-33 inhibitor and LXR activator on LXR-α and adenosine triphosphate-binding cassette transporter A1 (ABCA1) expression in mice liver. METHODS: Twenty-four mice were randomly allocated into four groups (n = 6). Group 1 mice received standard chow diet without any treatment, group 2 received 30 mg/kg/48 hour LXR agonist (T0901317), group 3 received 1 mg/kg/48 hour in vivo locked nucleic acids (LNA) anti-miR-33 and group 4 received both T0901317 and in vivo LNA anti-miR-33. All treatments were administrated through intraperitoneal injection (IP). After 7 days and at the end of the study, mice were sacrificed, liver tissues were excised and blood samples were collected. LXR-α and ABCA1 genes and protein expression were quantified by real-time polymerase chain reaction (PCR) and western blotting, respectively. RESULTS: LXR activation caused LXR-α and ABCA1 mRNA (P < 0.050) and protein elevation as compared to control (P < 0.001). miR-33 inhibition attenuates T0901317 effect on LXR-α expression in group IV. Co-administration of T0901317 and anti-miR-33 remarkably elevated high-density lipoprotein cholesterol (HDL-C) levels, compared to control group (P = 0.001). Separate administration of T0901317 and anti-miR-33 also elevated HDL-C levels (P < 0.010). CONCLUSION: Co-administration of T0901317 and anti-miR-33 can be considered as a good therapeutic alternative for atherosclerosis because miR-33 inhibition reduced lipogenic effects of LXR-α activator and also helps LXR-α agonist to increase reverse cholesterol transport (RCT) and also HDL-C as antiatherogenic effects.   

miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver Keywords:

miR-33 inhibition attenuates the effect of liver X receptor agonist T0901317 on expression of liver X receptor alpha in mice liver authors

Abbas Mohammadi

Professor, Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman AND Sirjan School of Medical Sciences, Sirjan, Iran

Hossein Fallah

Assistant Professor, Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine,, Kerman University of Medical Sciences, Kerman, Iran

Beydolah Shahouzehi

Physiology Research Center AND Department of Clinical Biochemistry, Afzalipour School of Medicine Kerman University of Medical Sciences, Kerman, Iran

Hamid Najafipour

Professor, Physiology Research Center AND Department of Physiology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
Najafi-Shoushtari SH. MicroRNAs in cardiometabolic disease. Curr Atheroscler Rep ۲۰۱۱; ...
Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M, ...
Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA۱ and ...
Annema W, Dikkers A, de Boer JF, Gautier T, Rensen ...
Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, ...
Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. ...
Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, ...
Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, ...
Calkin AC, Tontonoz P. Liver x receptor signaling pathways and ...
Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. ...
Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, ...
Chisholm JW, Hong J, Mills SA, Lawn RM. The LXR ...
Baranowski M. Biological role of liver X receptors. J Physiol ...
Ma Z, Deng C, Hu W, Zhou J, Fan C, ...
Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, ...
Li M, Meng X, Xu J, Huang X, Li H, ...
Yap F, Craddock L, Yang J. Mechanism of AMPK suppression ...
Lee J, Hong SW, Park SE, Rhee EJ, Park CY, ...
He F, Han C, Liu D, Wan H, Wang J, ...
Kostopoulou F, Malizos KN, Papathanasiou I, Tsezou A. MicroRNA-۳۳a regulates ...
Najafipour H, Vakili A, Shahouzehi B, Soltani HA, Masoomi Y, ...
Zheng F, Zhang S, Lu W, Wu F, Yin X, ...
Fulco M, Sartorelli V. Comparing and contrasting the roles of ...
Rohrl C, Eigner K, Winter K, Korbelius M, Obrowsky S, ...
Bommer GT, MacDougald OA. Regulation of lipid homeostasis by the ...
Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, ...
Gharipour M, Sadeghi M. Pivotal role of microRNA-۳۳ in metabolic ...
Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, ...
Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, ...
نمایش کامل مراجع